Investors Are Fleeing These 10 Stocks

Page 3 of 3

4. Icahn Enterprises Ltd. (NASDAQ:IEP)

Icahn Enterprises fell by 11.39 percent on Tuesday to close at $3.19 apiece, as investors disposed of its shares following the ex-date for its next dividend payment.

It can be recalled that the company’s board of directors approved the distribution of $0.50 in dividends to all depositary unit holders of November 16 record, payable on December 23. The dividends form part of Icahn Enterprises LP’s (NASDAQ:IEP) quarterly dividends.

The distribution announcement followed Icahn Enterprises LP’s (NASDAQ:IEP) earnings results in the third quarter of the year, where it swung to an attributable net loss of $225 million from a $287 million net income in the same period last year amid refining hedges in the investment funds attributable to the company.

Revenues, on the other hand, increased by 16 percent to $3.17 billion from $2.7 billion year-on-year, with net sales contributing to the bulk at $3.549 billion, or 53 percent higher than $2.3 billion year-on-year.

However, the higher net sales were offset by losses from investment activities, at $779 million versus $48 million in the same comparable period.

Adjusted EBITDA attributable to the company ended at a loss of $214 million, as compared with a $75 million adjusted EBITDA year-on-year.

3. Nextpower Inc. (NASDAQ:NXT)

Nextpower saw its share prices fall by 12.13 percent on Tuesday to finish at $78.48 apiece, as investors took path from two investment firms’ lower price targets for its stock.

In separate market notes on the same day, JPMorgan and BMO Capital both reduced their price targets for the stock, while maintaining overweight and outperform ratings.

JPMorgan now prices the company at $133 versus $134 previously, while BMO Capital dropped its target to $108 from $114 earlier.

For its part, BMO Capital said that while Nextpower Inc. (NASDAQ:NXT) outlined a rosier growth opportunity for fiscal year 2030, its 2028 margin commentary effectively lowered near-term profit expectations.

It said that another year of investment could delay operating leverage, which could materialize only in fiscal 2029 and 2030.

BMO Capital said that Nextpower Inc.’s broader product portfolio and higher fiscal 2030 earnings forecasts support its strategy to capture a larger share of customer spending, although the financial benefits are taking longer than anticipated.

2. Shoals Technologies Group Inc. (NASDAQ:SHLS)

Shoals Technologies dropped for a second day on Tuesday, slashing 12.22 percent to finish at $7.04 apiece, as investor sentiment was dampened by a downgrade from UBS amid uncertainties surrounding its merger with Array Technologies.

In a market note on the same day, the investment firm downgraded the stock to neutral from buy, as well as its price target to $9 from $12, saying that its proposed merger with Array cannot be considered a finished product, but a move that is overall positive.

UBS said that it expects further mergers and acquisitions into tangential product categories likely after the closing.

The investment firm raised its cumulative adjusted EBITDA estimates by 5 percent between 2026 and 2028 to reflect Shoals Technologies Group Inc.’s (NASDAQ:SHLS) results in the third quarter of the year and higher gross margins driven by the consolidation of manufacturing activities at the company’s new facility.

In the third quarter of the year, Shoals Technologies Group Inc. said that its net income surged by 50 percent in the third quarter of the year to $17.87 million from $11.88 million in the same period last year.

Revenues jumped by 43.8 percent to $195.3 million from $135.8 million year-on-year.

1. Omeros Corporation (NASDAQ:OMER)

Omeros Corp. (NASDAQ:OMER) fell by 16.55 percent on Tuesday to close at $13.92 apiece, after incurring wider losses in the third quarter of the year.

In an updated report, the company said that its net loss fell by 85 percent to $57.3 million from $30.9 million in the same period last year, dragged down by a non-cash loss of $62 million primarily related to mark-to-market adjustments of a derivative associated with its unsecured convertible notes due 2029.

Meanwhile, it incurred $35.9 million in product sales, thanks to the strong uptake of Yartemlea—the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy.

“Yartemlea sales continued to grow during the third quarter, delivering consecutive quarters of positive operating cash flow,” Omeros Corporation Chairman and CEO Gregory Demopulos said.

“As expected, 340B participation increased, reflecting substantial expansion of our customer base and increased outpatient use of Yartemlea. That momentum has continued into the fourth quarter, with Yartemlea revenues continuing to grow,” he noted.

In other news, Omeros Corporation announced last month that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) thumbed down its marketing authorization application for narsoplimab, under the brand name Yartemlea, for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) following re-examination of its original negative opinion adopted in June 2026.

An eight-member ad hoc expert group (AHEG) consisting of hematologists, statisticians, and transplant physicians, together with two patient representatives, was convened by CHMP as part of the re-examination process.

“We are deeply disappointed in the re-examination process and outcome…We believe that our Yartemlea efficacy and safety data, FDA’s recent approval with a broad indication for both adults and children, a decade of compassionate use requests by European transplant physicians for their TA-TMA patients, and the rapid US commercial adoption speak clearly to the favorable benefit-risk profile of the drug,” he noted.

READ NEXT: Forget Nvidia: 10 Stocks Wall Street is Betting on Right Now and Buy Alert: 10 Stocks Analysts Upgraded on Friday

Follow Insider Monkey on Google News.

Page 3 of 3